Lifetime GLP-1 agonist use hits 32.1% in eating disorder groups, well above the 15% general rate, with misuse tied to rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results